A detailed history of Srs Capital Advisors, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 2,465 shares of LLY stock, worth $1.8 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
2,465
Previous 2,447 0.74%
Holding current value
$1.8 Million
Previous $2.22 Million 1.44%
% of portfolio
0.2%
Previous 0.23%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$772.14 - $960.02 $13,898 - $17,280
18 Added 0.74%
2,465 $2.18 Million
Q2 2024

Aug 06, 2024

BUY
$724.87 - $909.04 $358,810 - $449,974
495 Added 25.36%
2,447 $2.22 Million
Q1 2024

May 14, 2024

SELL
$592.2 - $792.28 $26,649 - $35,652
-45 Reduced 2.25%
1,952 $1.52 Million
Q4 2023

Feb 06, 2024

SELL
$525.19 - $619.13 $80,354 - $94,726
-153 Reduced 7.12%
1,997 $1.16 Million
Q3 2023

Nov 14, 2023

SELL
$434.7 - $599.3 $14,779 - $20,376
-34 Reduced 1.56%
2,150 $1.15 Million
Q2 2023

Aug 14, 2023

BUY
$350.74 - $468.98 $2,805 - $3,751
8 Added 0.37%
2,184 $1.02 Million
Q1 2023

May 16, 2023

BUY
$310.63 - $364.82 $30,131 - $35,387
97 Added 4.67%
2,176 $747,000
Q4 2022

Feb 24, 2023

BUY
$321.55 - $374.67 $38,264 - $44,585
119 Added 6.07%
2,079 $760,000
Q3 2022

Nov 03, 2022

SELL
$296.48 - $337.87 $161,581 - $184,139
-545 Reduced 21.76%
1,960 $634,000
Q2 2022

Aug 22, 2022

BUY
$278.73 - $327.27 $248,069 - $291,270
890 Added 55.11%
2,505 $812,000
Q1 2022

May 12, 2022

BUY
$234.69 - $291.66 $4,224 - $5,249
18 Added 1.13%
1,615 $462,000
Q4 2021

Feb 08, 2022

BUY
$224.85 - $279.04 $674 - $837
3 Added 0.19%
1,597 $441,000
Q3 2021

Nov 05, 2021

BUY
$221.6 - $272.71 $10,415 - $12,817
47 Added 3.04%
1,594 $368,000
Q2 2021

Aug 02, 2021

BUY
$180.55 - $233.54 $2,708 - $3,503
15 Added 0.98%
1,547 $355,000
Q4 2020

Feb 03, 2021

BUY
$130.46 - $172.63 $521 - $690
4 Added 0.26%
1,532 $259,000
Q3 2020

Nov 12, 2020

BUY
$146.22 - $169.13 $14,475 - $16,743
99 Added 6.93%
1,528 $226,000
Q2 2020

Aug 06, 2020

BUY
$136.42 - $164.18 $545 - $656
4 Added 0.28%
1,429 $235,000
Q1 2020

May 13, 2020

BUY
$119.05 - $147.35 $98,335 - $121,711
826 Added 137.9%
1,425 $198,000
Q2 2019

Aug 08, 2019

BUY
$110.79 - $129.32 $63,482 - $74,100
573 Added 2203.85%
599 $66,000
Q3 2018

Nov 06, 2018

SELL
$85.86 - $107.31 $53,490 - $66,854
-623 Reduced 95.99%
26 $3,000
Q2 2018

Aug 21, 2018

BUY
$75.7 - $86.88 $16,199 - $18,592
214 Added 49.2%
649 $55,000
Q1 2018

May 14, 2018

BUY
$74.21 - $87.6 $6,901 - $8,146
93 Added 27.19%
435 $33,000
Q4 2017

Feb 15, 2018

BUY
$81.94 - $87.89 $5,981 - $6,415
73 Added 27.14%
342 $28,000
Q3 2017

Nov 15, 2017

BUY
$77.07 - $85.54 $20,731 - $23,010
269
269 $23,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $693B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Srs Capital Advisors, Inc. Portfolio

Follow Srs Capital Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Srs Capital Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Srs Capital Advisors, Inc. with notifications on news.